Bladder Cancer Journal Vol. 10, Issue 1
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read MoreSelect Page
by Bladder Cancer Journal | Mar 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read Moreby Bladder Cancer Journal | Dec 2023
What is a Bladder Cancer Molecular Subtype? Abstract:Â BACKGROUND: Several molecular...
Read Moreby Bladder Cancer Journal | Sep 2023
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is...
Read Moreby Bladder Cancer Journal | Jun 2023
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer...
Read Moreby Bladder Cancer Journal | Mar 2023
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the...
Read Moreby Daniel P. Petrylak, MD | Jan 2023
Daniel P. Petrylak, MD, explores immune checkpoint inhibitors for the management of bladder cancer, especially metastatic urothelial carcinoma.
Read Moreby Bladder Cancer Journal | Dec 2022
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer:...
Read Moreby Bladder Cancer Journal | Sep 2022
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors Abstract:Â ...
Read Moreby Bladder Cancer Journal | Jun 2022
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer Abstract:Â ...
Read Moreby Bladder Cancer Journal | Mar 2022
Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple? Abstract: Marker...
Read Moreby Bladder Cancer Journal | Jan 2022
The Pros and Cons of “Machination of Medicine” in Genitourinary Practice ABSTRACT: The...
Read Moreby Bladder Cancer Journal | Sep 2021
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent...
Read More